Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"BRAF mutant"”.
-
P4HB TARGETING HALTS TUMOR GROWTH AND RE-SENSITIZES RESISTANT MELANOMA CELLS TO DABRAFENIB AND TRAMETINIB STANDARD-OF-CARE THERAPY VIA IRE1-⍺ ACTIVATION AND AKT DOWNMODULATION
BRAF-mutant melanoma patients account for approximately 50% of all cutaneous melanoma cases. The overall survival rate of metastatic melanoma patients was dramatically improved by the introduction of targeted therapy (BRAF and MEK inhibitors) and immune checkpoints inhibitors (anti-PD1, …
-
Tumor cell-intrinsic signals promoting tolerance and adaptation to oncogenic kinase inhibition
… underlying early adaptation to oncogenic BRAF inhibition in a patient-derived cell line model of human BRAF-mutant melanoma. We show by time-resolved MS of mitogenic signaling networks, computationally integrated with matched mRNA sequencing data, that adaptation to BRAF inhibition in our …
-
Analysis Of The Effects Of Metformin Administered Alone Or In Combined Treatments In Colorectal Cancer
… or proteins (targeted therapies), focusing on BRAF-mutant cell lines. For most of the tested treatments the simultaneous administration of metformin and target drugs gave no advantages over the single drugs, and often resulted in antagonism. Overall, our results show that although further …
-
Metabolomic Investigation of Melanoma Metastasis in a Patient-Derived Xenograft Mouse Model
… molecular and biological features of the tumors. BRAF-mutant tumors had metabolomic and metabolic flux features of enhanced glycolysis compared to BRAF-wild type tumors. Tumors that metastasized efficiently from their primary sites had elevated levels of metabolites related to protein methylation, …
-
Role of the Innate Immune Response to DNA During Therapy with Oncolytic Viruses
… to OV infection. After establishing the BRAF-mutant melanoma cell line 4434 as our model system, I found that deletion of cytoplasmic DNA sensor cyclic GMP-AMP Synthase (cGAS) resulted in loss of STING-dependent signalling in response to DNA stimulation and SKV infection whilst deletion …
-
Exploiting tumour cell dependency on pro-survival BCL2 proteins with BH3 mimetics
… in human cancer, with mutations in KRAS and BRAF commonly occurring in cancers of the pancreas, skin, and colon, among others. Indeed, BRAF and MEK1/2 inhibitors are approved for the treatment of BRAF-mutant malignant melanoma and are improving patient outcomes. However, the development of …
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… evaluated the ctDNA detection rate in untreated BRAF mutant melanoma patients, as a potential alternative to tumour genotyping (Chapter 3), where the potential economic benefit of implementing plasma ctDNA testing by ddPCR relative to tissue BRAF testing was also investigated. The study in …
-
Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer
… have an oncogenic V600E mutation in the kinase BRAF, which leads to a constitutively active and oncogenic kinase. This mutation has been associated with as well as a 2.14-fold increase in recurrent/persistent disease. Excitingly, inhibitors against this mutant kinase or its substrates, the …
-
A NOVEL BRAF SIGNALING CASCADE THROUGH p-21 ACTIVATED KINASES REGULATES THYROID CANCER CELL MOTILITY
… is the presence of the activating mutation BRAF V600E. From our prior studies, we determined that the invasive fronts of aggressive PTC exhibited a characteristic change in morphology known as epithelial-to-mesenchymal transition (EMT). EMT has been linked to aggressive or late stage tumor …
-
Circulating tumour DNA: A non-invasive biomarker for melanoma
… life and survival. The detection and analysis of mutant specific circulating tumour DNA (ctDNA) is an emerging tool for detection of residual disease and for prognosis and monitoring of different cancers (Bettegowda et al., 2014; Dawson et al., 2013; Gray et al., 2015; Spindler et al., 2012). …